首页> 外文OA文献 >Two Methods for Converting a Heavy-Water Research Reactor to Use Low-Enriched-Uranium Fuel to Improve Proliferation Resistance After Startup
【2h】

Two Methods for Converting a Heavy-Water Research Reactor to Use Low-Enriched-Uranium Fuel to Improve Proliferation Resistance After Startup

机译:改造重水研究堆使用低浓铀燃料提高启动后抗增殖能力的两种方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This article demonstrates the feasibility of converting a heavy-water research reactor from natural to low-enriched uranium in order to slow the production of weapon-usable plutonium, even if the core cannot be physically reconfigured. The analysis was performed for Iran’s IR-40 reactor at Arak in support of negotiations with Iran, but the methods have application to future reactors that present similar nonproliferation challenges. Two methods are considered, and both retain identical power, thermal-hydraulic, and safety profiles as the original reactor design. The conversion options can be implemented at any time during the reactor’s life. The two methods have competing effects on achievable burnup, and they can be combined to produce an optimized core that matches both the fresh-core reactivity and maximum burnup of the original reactor. For the IR-40 example, the optimized design produces weapon-grade plutonium at only about 19% of the rate of the unmodified reactor for the same power level. Additionally, a reactor so converted could not be readily converted back to natural-uranium fuel without replacement heavy water, and it would retain the ability to produce medical isotopes at rates that exceed the original design through the use of LEU targets.
机译:本文论证了将重水研究堆从天然铀转化为低浓铀的可行性,以减慢可用于武器的p的生产,即使无法对堆芯进行物理重组。分析是在伊朗阿拉克的IR-40反应堆中进行的,以支持与伊朗的谈判,但该方法已应用于未来提出类似防扩散挑战的反应堆。考虑了两种方法,它们都保留了与原始反应堆设计相同的功率,热工液压和安全特性。转换选项可以在反应堆使用期间的任何时间实施。两种方法对可达到的燃耗具有竞争性影响,可以将它们组合使用以产生与原始反应堆的新鲜堆芯反应性和最大燃耗相匹配的优化堆芯。以IR-40为例,优化设计可在相同功率水平下以未改性反应堆速率的约19%产生武器级p。另外,如此转化的反应堆如果不更换重水就不能轻易地转化回天然铀燃料,并且通过使用LEU靶标,它仍将能够以超过原始设计的速率生产医学同位素。

著录项

  • 作者

    Kemp R. Scott;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 en_US
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号